CORONAVIRUS/Indonesia allows Taiwan's COVID-19 vaccine candidate to conduct clinical trial

09/13/2021 12:05 PM
To activate the text-to-speech service, please first agree to the privacy policy below.

Taipei, Sept. 13 (CNA) Taiwanese vaccine producer Adimmune Corp. said on Monday that it has gained approval from the Indonesian government to conduct Phase 2 clinical trials for its COVID-19 vaccine candidate, with results expected to be released next year.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)

View All
We value your privacy.
Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.